色素-话题@MedSci

#色素#

654篇内容 | 4965人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1680707, encodeId=32dc1680e078d, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, objectType=article, longId=205720, objectId=6c70205e20be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c70205e20be, replyNumber=0, likeNumber=59, createdTime=2021-05-15, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c70205e20be, moduleTitle=J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c70205e20be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680712, encodeId=3cb11680e123f, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, objectType=article, longId=206683, objectId=000c20668335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000c20668335, replyNumber=0, likeNumber=67, createdTime=2021-05-30, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000c20668335, moduleTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=000c20668335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680693, encodeId=52d5168069391, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , objectType=article, longId=201778, objectId=df60201e785f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df60201e785f, replyNumber=0, likeNumber=99, createdTime=2021-02-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df60201e785f, moduleTitle=Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df60201e785f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680673, encodeId=2e3e16806e33b, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Aging：黑色素瘤的新型免疫相关基因预后生物标志物：与肿瘤微环境相关, objectType=article, longId=194771, objectId=f72f194e7116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72f194e7116, replyNumber=0, likeNumber=91, createdTime=2020-10-28, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72f194e7116, moduleTitle=Aging：黑色素瘤的新型免疫相关基因预后生物标志物：与肿瘤微环境相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72f194e7116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680674, encodeId=59be16806e438, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, objectType=article, longId=195816, objectId=65141958168d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65141958168d, replyNumber=0, likeNumber=78, createdTime=2020-10-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65141958168d, moduleTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65141958168d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680669, encodeId=e771168066970, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet：Nivolumab用于IV期黑色素瘤的治疗, objectType=article, longId=194244, objectId=c4ff19424468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4ff19424468, replyNumber=0, likeNumber=64, createdTime=2020-07-26, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4ff19424468, moduleTitle=Lancet：Nivolumab用于IV期黑色素瘤的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4ff19424468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680699, encodeId=0c2b16806998d, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NEJM：十二指肠假性黑色素瘤-病例报道, objectType=article, longId=203310, objectId=4f8620331075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f8620331075, replyNumber=0, likeNumber=65, createdTime=2021-10-27, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f8620331075, moduleTitle=NEJM：十二指肠假性黑色素瘤-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f8620331075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680694, encodeId=4aa91680694a0, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, objectType=article, longId=201779, objectId=f6f5201e7983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6f5201e7983, replyNumber=0, likeNumber=55, createdTime=2021-08-16, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6f5201e7983, moduleTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6f5201e7983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680660, encodeId=402116806607e, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=上前牙牙龈色素痣1例, objectType=article, longId=189249, objectId=74b1189249d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b1189249d2, replyNumber=0, likeNumber=74, createdTime=2020-05-16, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b1189249d2, moduleTitle=上前牙牙龈色素痣1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b1189249d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680665, encodeId=abd616806656c, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Cell Death Diff：成纤维细胞PPARβ/δ缺失可减少抑制非黑色素瘤皮肤癌发生, objectType=article, longId=192819, objectId=295d192819d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=295d192819d1, replyNumber=0, likeNumber=63, createdTime=2020-05-09, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=295d192819d1, moduleTitle=Cell Death Diff：成纤维细胞PPARβ/δ缺失可减少抑制非黑色素瘤皮肤癌发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=295d192819d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680690, encodeId=c0111680690f8, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet oncol：纳武单抗维持高危黑色素瘤术后辅助治疗的长期疗效明显优于伊匹单抗, objectType=article, longId=201125, objectId=c5a52011256e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5a52011256e, replyNumber=0, likeNumber=51, createdTime=2021-08-20, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5a52011256e, moduleTitle=Lancet oncol：纳武单抗维持高危黑色素瘤术后辅助治疗的长期疗效明显优于伊匹单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5a52011256e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680695, encodeId=e62c168069512, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, objectType=article, longId=201995, objectId=a7e920199565, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7e920199565, replyNumber=0, likeNumber=73, createdTime=2021-08-01, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7e920199565, moduleTitle=免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7e920199565)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680704, encodeId=dcfc1680e0484, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NATURE：黑色素瘤如何对抗肿瘤免疫做出反应？, objectType=article, longId=204664, objectId=e6dd204664c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6dd204664c4, replyNumber=0, likeNumber=50, createdTime=2021-03-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6dd204664c4, moduleTitle=NATURE：黑色素瘤如何对抗肿瘤免疫做出反应？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6dd204664c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680705, encodeId=46941680e05b3, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤, objectType=article, longId=205435, objectId=735520543511, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735520543511, replyNumber=0, likeNumber=70, createdTime=2021-08-18, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735520543511, moduleTitle=Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=735520543511)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680653, encodeId=b8f4168065337, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=NEJM：氟尿嘧啶诱导的色素沉着-病例报道, objectType=article, longId=186675, objectId=d3731866e516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3731866e516, replyNumber=0, likeNumber=66, createdTime=2020-03-20, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3731866e516, moduleTitle=NEJM：氟尿嘧啶诱导的色素沉着-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3731866e516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680703, encodeId=fe071680e03fd, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定, objectType=article, longId=204616, objectId=b52e2046165f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52e2046165f, replyNumber=0, likeNumber=72, createdTime=2021-07-24, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52e2046165f, moduleTitle=肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b52e2046165f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680680, encodeId=32ee168068017, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=黑色素性神经鞘瘤2例报道, objectType=article, longId=198388, objectId=d206198388fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d206198388fd, replyNumber=0, likeNumber=66, createdTime=2020-10-07, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d206198388fd, moduleTitle=黑色素性神经鞘瘤2例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d206198388fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680652, encodeId=c578168065298, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=2019 欧洲多学科共识指南：黑色素瘤的诊断, objectType=article, longId=186665, objectId=f9571866654d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9571866654d, replyNumber=0, likeNumber=10, createdTime=2020-03-28, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9571866654d, moduleTitle=2019 欧洲多学科共识指南：黑色素瘤的诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9571866654d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680656, encodeId=ef21168065622, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, objectType=article, longId=187354, objectId=313c18e3543f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313c18e3543f, replyNumber=0, likeNumber=82, createdTime=2020-12-03, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313c18e3543f, moduleTitle=Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313c18e3543f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1680702, encodeId=7ef31680e0267, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, objectTitle=Nat Commun：SOX2/GLI1-ST3GAL1-AXL通路促进黑色素瘤的转移, objectType=article, longId=203833, objectId=59f82038336b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59f82038336b, replyNumber=0, likeNumber=55, createdTime=2021-09-21, rootId=0, userName=sunylz, userId=343027846633, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59f82038336b, moduleTitle=Nat Commun：SOX2/GLI1-ST3GAL1-AXL通路促进黑色素瘤的转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59f82038336b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

色素

2020-05-29

sunylz (审核中...)

前往app查看评论内容

#色素#

J Immunother Cancer：采用免疫检查点抑制剂治疗的黑色素瘤患者静脉血栓栓塞的发生率

2021-05-15

sunylz (审核中...)

前往app查看评论内容

#色素#

Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

2021-05-30

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Med: II期临床试验: 黑色素瘤患者应该持续还是间歇给药？

2021-02-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Aging：黑色素瘤的新型免疫相关基因预后生物标志物：与肿瘤微环境相关

2020-10-28

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤

2020-10-24

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet：Nivolumab用于IV期黑色素瘤的治疗

2020-07-26

sunylz (审核中...)

前往app查看评论内容

#色素#

NEJM：十二指肠假性黑色素瘤-病例报道

2021-10-27

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤

2021-08-16

sunylz (审核中...)

前往app查看评论内容

#色素#

上前牙牙龈色素痣1例

2020-05-16

sunylz (审核中...)

前往app查看评论内容

#色素#

Cell Death Diff：成纤维细胞PPARβ/δ缺失可减少抑制非黑色素瘤皮肤癌发生

2020-05-09

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet oncol：纳武单抗维持高危黑色素瘤术后辅助治疗的长期疗效明显优于伊匹单抗

2021-08-20

sunylz (审核中...)

前往app查看评论内容

#色素#

免疫联合疗法O药+Y药：黑色素瘤辅助治疗的III期临床失败

2021-08-01

sunylz (审核中...)

前往app查看评论内容

#色素#

NATURE：黑色素瘤如何对抗肿瘤免疫做出反应？

2021-03-07

sunylz (审核中...)

前往app查看评论内容

#色素#

Clin Cancer Res：纳武单抗+伊匹单抗+英夫利昔单抗/赛妥珠单抗治疗黑色素瘤

2021-08-18

sunylz (审核中...)

前往app查看评论内容

#色素#

NEJM：氟尿嘧啶诱导的色素沉着-病例报道

2020-03-20

sunylz (审核中...)

前往app查看评论内容

#色素#

肿瘤疫苗+PD1，黑色素瘤患者完全缓解率45%！获得FDA突破性疗法认定

2021-07-24

sunylz (审核中...)

前往app查看评论内容

#色素#

黑色素性神经鞘瘤2例报道

2020-10-07

sunylz (审核中...)

前往app查看评论内容

#色素#

2019 欧洲多学科共识指南：黑色素瘤的诊断

2020-03-28

sunylz (审核中...)

前往app查看评论内容

#色素#

Lancet Oncol：肿瘤突变负荷联合IFNγ基因表达特征可预测靶向治疗的III期黑色素瘤患者的预后

2020-12-03

sunylz (审核中...)

前往app查看评论内容

#色素#

Nat Commun：SOX2/GLI1-ST3GAL1-AXL通路促进黑色素瘤的转移

2021-09-21

科室
- - 订阅+
  - 更多科室
工具
服务